Francesco Di Raimondo

List of Publications by Year
in descending order

357	16,512	23567 58	19190 118
papers	citations	h-index	g-index

358	358	358	15212
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BRAFMutations in Hairy-Cell Leukemia. New England Journal of Medicine, 2011, 364, 2305-2315.	27.0	949
2	Early Interim 2-[¹⁸F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. Journal of Clinical Oncology, 2007, 25, 3746-3752.	1.6	799
3	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, The, 2010, 376, 2075-2085.	13.7	770
4	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. New England Journal of Medicine, 2014, 371, 895-905.	27.0	683
5	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. Journal of Clinical Oncology, 2009, 27, 4555-4562.	1.6	613
6	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	13.7	517
7	Treatment of Older Patients with Mantle-Cell Lymphoma. New England Journal of Medicine, 2012, 367, 520-531.	27.0	465
8	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosomeâ€“positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood, 2007, 109, 3676-3678.	1.4	336
9	Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study. Journal of Clinical Oncology, 2007, 25, 2434-2441.	1.6	329
10	Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood, 2002, 99, 863-871.	1.4	325
11	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€"Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	1.6	301
12	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010, 116, 3171-3179.	1.4	290
13	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, 119, 933-939.	1.4	260
14	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
15	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood, 2008, 111, 4004-4013.	1.4	243
16	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood, 2011, 118, 6153-6163.	1.4	227
17	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood, 2011, 118, 4554-4560.	1.4	221
18	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Journal of Clinical Oncology, 2014, 32, 634-640.	1.6	198

#	Article	IF	Citations
19	The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia, 2015, 29, 1336-1343.	7.2	191
20	Gene Expression Profiling of Hairy Cell Leukemia Reveals a Phenotype Related to Memory B Cells with Altered Expression of Chemokine and Adhesion Receptors. Journal of Experimental Medicine, 2004, 199, 59-68.	8.5	181
21	Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10. Journal of Clinical Oncology, 2009, 27, 5397-5403.	1.6	180
22	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood, 2005, 105, 3434-3441.	1.4	178
23	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood, 2011, 117, 4716-4725.	1.4	173
24	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood, 2016, 128, 497-503.	1.4	144
25	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	1.6	138
26	VÎ³9VÎ´2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells. Journal of Immunology, 2010, 184, 3260-3268.	0.8	132
27	Early chemotherapy intensification with BEACOPP in advancedâ€stage Hodgkin lymphoma patients with a interimâ€PET positive after two ABVD courses. British Journal of Haematology, 2011, 152, 551-560.	2.5	127
28	CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leukemia Research, 2009, 33, 1212-1216.	0.8	124
29	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Annals of Oncology, 2013, 24, 2108-2112.	1.2	124
30	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood, 2015, 125, 3455-3465.	1.4	124
31	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica, 2013, 98, 1702-1710.	3.5	121
32	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood, 2013, 121, 4902-4905.	1.4	113
33	Immunological Dysregulation in Multiple Myeloma Microenvironment. BioMed Research International, 2014, 2014, 1-10.	1.9	106
34	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
35	Chlorambucil plus rituximab with or without maintenance rituximab as firstâ€line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology, 2014, 89, 480-486.	4.1	104
36	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood, 2010, 116, 3907-3922.	1.4	100

#	Article	IF	Citations
37	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2002, 100, 974-981.	1.4	99
38	Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica, 2009, 94, 1391-1398.	3.5	96
39	A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. European Journal of Cancer & Clinical Oncology, 1991, 27, 750-755.	0.7	92
40	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood, 2006, 108, 4146-4155.	1.4	92
41	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clinical Cancer Research, 2013, 19, 3130-3142.	7.0	86
42	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood, 2013, 122, 3759-3766.	1.4	82
43	Nuclear Translocation of Heme Oxygenase-1 Confers Resistance to Imatinib in Chronic Myeloid Leukemia Cells. Current Pharmaceutical Design, 2013, 19, 2765-2770.	1.9	80
44	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget, 2016, 7, 85764-85775.	1.8	80
45	Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer, 2003, 97, 114-120.	4.1	78
46	Safety and efficacy of bortezomibâ€based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology, 2010, 84, 223-228.	2.2	77
47	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia, 2014, 28, 222-225.	7.2	77
48	Circulating myeloidâ€derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated upâ€front with a riskâ€adapted strategy. British Journal of Haematology, 2015, 168, 689-700.	2.5	76
49	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
50	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2014, 9, e101848.	2.5	71
51	Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. International Journal of Cancer, 2012, 131, 2197-2203.	5.1	70
52	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2011, 50, 633-643.	2.8	67
53	Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology, 2018, 4, 1389.	7.1	67
54	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. Journal of Clinical Oncology, 2016, 34, 4015-4022.	1.6	66

#	Article	IF	Citations
55	Temsirolimus, an mTOR inhibitor, in combination with lowerâ€dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AMLâ€1107). British Journal of Haematology, 2012, 156, 205-212.	2.5	65
56	E2Aâ€“PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. British Journal of Haematology, 2003, 120, 484-487.	2.5	63
57	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Medicine, 2019, 8, 2041-2055.	2.8	63
58	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	1.8	63
59	PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. Expert Review of Molecular Diagnostics, 2018, 18, 675-683.	3.1	61
60	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e401-e419.	0.4	61
61	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020, 135, 534-541.	1.4	61
62	Genomeâ€wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. American Journal of Hematology, 2013, 88, 16-23.	4.1	60
63	Clinical Monoclonal B Lymphocytosis versus Rai 0 Chronic Lymphocytic Leukemia: A Comparison of Cellular, Cytogenetic, Molecular, and Clinical Features. Clinical Cancer Research, 2013, 19, 5890-5900.	7.0	60
64	Angiogenesis in Chronic Myeloproliferative Diseases. Acta Haematologica, 2001, 106, 177-183.	1.4	59
65	Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs. Molecular Cancer Therapeutics, 2013, 12, 1085-1098.	4.1	59
66	Consequences of metaphase II oocyte cryopreservation on mRNA content. Cryobiology, 2011, 62, 130-134.	0.7	58
67	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. American Journal of Hematology, 2016, 91, 1090-1095.	4.1	58
68	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leukemia Research, 2004, 28, 469-477.	0.8	57
69	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget, 2015, 6, 17543-17558.	1.8	55
70	Liposomal daunorubicin versus standard daunorubicin: long term followâ€up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60â€fyears with acute myelogenous leukaemia. British Journal of Haematology, 2008, 143, 681-689.	2.5	54
71	Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. Expert Review of Anticancer Therapy, 2016, 16, 273-278.	2.4	54
72	Management of Chronic Myeloid Leukemia in Advanced Phase. Frontiers in Oncology, 2019, 9, 1132.	2.8	54

#	Article	IF	Citations
73	Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood, 2006, 108, 3951-3952.	1.4	53
74	Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. Oncotarget, 2016, 7, 28868-28880.	1.8	53
75	Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. Molecular Cancer, 2018, 17, 56.	19.2	53
76	Highâ€throughput sequencing for the identification of <scp>NOTCH</scp>1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. British Journal of Haematology, 2014, 165, 629-639.	2.5	52
77	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. Journal of Clinical Oncology, 2016, 34, 8000-8000.	1.6	52
78	Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Acta OncolÃ³gica, 2010, 49, 506-508.	1.8	51
79	Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up. World Journal of Gastroenterology, 2014, 20, 12993.	3.3	49
80	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica, 2021, 106, 1559-1568.	3.5	49
81	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood, 2013, 122, 3317-3321.	1.4	48
82	Determination of chitinases family during osteoclastogenesis. Bone, 2014, 61, 55-63.	2.9	48
83	Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Annals of Hematology, 2015, 94, 1875-1883.	1.8	47
84	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2007, 109, 5473-5476.	1.4	46
85	Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 5001-5007.	1.6	46
86	Amyloid in bone marrow smears of patients affected by multiple myeloma. Annals of Hematology, 2010, 89, 469-474.	1.8	46
87	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Annals of Hematology, 2018, 97, 1009-1018.	1.8	44
88	Effects of imatinib mesylate in osteoblastogenesis. Experimental Hematology, 2009, 37, 461-468.	0.4	41
89	Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells. Biomolecules, 2020, 10, 696.	4.0	39
90	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood, 2003, 102, 2014-2020.	1.4	38

#	Article	IF	Citations
91	Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. Infectious Agents and Cancer, 2016, 11, 27.	2.6	38
92	The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. Blood Cancer Journal, 2017, 7, 649.	6.2	37
93	Î±-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload. International Journal of Molecular Sciences, 2019, 20, 609.	4.1	37
94	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. PLoS ONE, 2011, 6, e24313.	2.5	36
95	Monocytic myeloidâ€derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. Journal of Cellular and Molecular Medicine, 2018, 22, 1070-1080.	3.6	36
96	Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines. European Journal of Medicinal Chemistry, 2018, 158, 937-950.	5.5	36
97	TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. Cell Death and Disease, 2019, 10, 704.	6.3	36
98	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 116, 774-780.	2.5	35
99	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Reviews, 2019, 34, 84-94.	5.7	35
100	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood, 2011, 118, 5759-5766.	1.4	34
101	BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint. Acta Haematologica, 2011, 126, 205-210.	1.4	34
102	The Heme Oxygenase System in Hematological Malignancies. Antioxidants and Redox Signaling, 2017, 27, 363-377.	5.4	34
103	High BCRâ€“ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib. Clinical Cancer Research, 2017, 23, 7189-7198.	7.0	34
104	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematology,the, 2020, 7, e861-e873.	4.6	34
105	IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. Carcinogenesis, 2014, 35, 1132-1143.	2.8	33
106	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood, 2020, 135, 1244-1254.	1.4	33
107	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. Haematologica, 2021, 106, 1828-1838.	3.5	33
108	Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview. Frontiers in Oncology, 2020, 10, 604143.	2.8	32

#	Article	IF	Citations
109	Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. Leukemia Research, 2010, 34, 1539-1542.	0.8	31
110	CHI3L1 nuclear localization in monocyte derived dendritic cells. Immunobiology, 2016, 221, 347-356.	1.9	31
111	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2016, 11, e0158392.	2.5	30
112	Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib. Redox Biology, 2020, 36, 101611.	9.0	30
113	Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Annals of Hematology, 2009, 88, 967-971.	1.8	29
114	BCRâ€ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. FASEB Journal, 2014, 28, 1221-1236.	0.5	29
115	Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM). Nutrients, 2016, 8, 611.	4.1	29
116	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica, 2020, 105, 193-200.	3.5	29
117	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. British Journal of Haematology, 2000, 109, 788-793.	2.5	28
118	Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia. Acta Haematologica, 2008, 120, 19-30.	1.4	28
119	ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives. Anticancer Research, 2020, 40, 2457-2465.	1.1	28
120	Trisomy 8 in philadelphia chromosome (ph1)-negative cells in the course of ph1-positive chronic myelocytic leukemia. Genes Chromosomes and Cancer, 1992, 4, 269-270.	2.8	27
121	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. British Journal of Haematology, 2003, 120, 405-412.	2.5	27
122	Chromosome 2p gain in monoclonal Bâ€cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	4.1	27
123	A populationâ€based study of chronic myeloid leukemia patients treated with imatinib in first line. American Journal of Hematology, 2017, 92, 82-87.	4.1	27
124	The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. Oncotarget, 2016, 7, 67333-67346.	1.8	27
125	Effects of secondâ€generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematological Oncology, 2012, 30, 27-33.	1.7	26
126	Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib. Molecular Neurobiology, 2019, 56, 1451-1460.	4.0	25

#	Article	IF	Citations
127	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	3.4	24
128	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3150-3158.	1.3	23
129	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Longâ€term results and prognostic factors. British Journal of Haematology, 2011, 154, 564-568.	2.5	22
130	Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy, 2013, 5, 327-352.	2.0	22
131	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. European Journal of Cancer, 2016, 60, 154-165.	2.8	22
132	<scp>NOTCH</scp>1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. British Journal of Haematology, 2018, 182, 597-602.	2.5	22
133	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica, 2019, 104, 1640-1647.	3.5	22
134	Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. Frontiers in Oncology, 2019, 9, 57.	2.8	22
135	Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells. Cancers, 2020, 12, 323.	3.7	22
136	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology, 2009, 82, 93-105.	2.2	21
137	Vertebroplasty in multiple myeloma with osteolysis or fracture of the posterior vertebral wall. Usefulness of a delayed cement injection. Skeletal Radiology, 2011, 40, 913-919.	2.0	21
138	Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation. Inflammation, 2015, 38, 2082-2091.	3.8	21
139	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	7.2	21
140	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. BMC Medical Genomics, 2009, 2, 20.	1.5	20
141	Sacroplasty for Local or Massive Localization of Multiple Myeloma. CardioVascular and Interventional Radiology, 2010, 33, 1270-1277.	2.0	20
142	Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network. Journal of Clinical Medicine, 2019, 8, 877.	2.4	20
143	Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive. Blood, 2013, 122, 3138-3138.	1.4	20
144	Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma. Haematologica, 2012, 97, e21-e23.	3.5	19

#	Article	IF	Citations
145	Lenalidomide and lowâ€dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. American Journal of Hematology, 2017, 92, 244-250.	4.1	19
146	Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Phâ€™+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. Chemotherapy, 2018, 63, 220-224.	1.6	19
147	Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3. International Journal of Molecular Sciences, 2019, 20, 3548.	4.1	19
148	CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis, 2022, 11, 6.	4.9	19
149	Pleuric presentation of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a case report and a review of the literature. International Journal of Hematology, 2010, 92, 369-373.	1.6	18
150	Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients. Clinical Drug Investigation, 2011, 31, 745-758.	2.2	18
151	Bone Turnover Markers in Patients with Type 1 Gaucher Disease. Hematology Reports, 2012, 4, e21.	0.8	18
152	Primary plasma cell leukemia in the era of new drugs: Has something changed?. Critical Reviews in Oncology/Hematology, 2012, 82, 141-149.	4.4	18
153	Salvage Therapy of Multiple Myeloma: The New Generation Drugs. BioMed Research International, 2014, 2014, 1-14.	1.9	18
154	Mutations in the 3â€² untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia. Haematologica, 2017, 102, e305-e309.	3.5	18
155	BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.. Blood, 2010, 116, 3426-3426.	1.4	18
156	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. Oncotarget, 2015, 6, 19102-19117.	1.8	18
157	CD200 expression in patients with Multiple Myeloma: Another piece of the puzzle. Leukemia Research, 2013, 37, 1616-1621.	0.8	17
158	IMMUNOLOGICAL DEREGULATION IN HODGKINâ€™S DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014039.	1.3	17
159	Prognostic Assessment and Treatment of Primary Gastric Lymphomas: How Endoscopic Ultrasonography Can Help in Tailoring PatientÂManagement. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 179-185.	0.4	17
160	miR-155 regulative network in FLT3 mutated acute myeloid leukemia. Leukemia Research, 2015, 39, 883-896.	0.8	17
161	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. International Journal of Molecular Sciences, 2019, 20, 5459.	4.1	17
162	Immune offâ€target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. British Journal of Haematology, 2019, 185, 468-479.	2.5	17

#	Article	IF	Citations
163	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica, 2020, 106, 291-294.	3.5	17
164	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 2021, 35, 235-238.	7.2	17
165	Hyperdiploidy Associated with a High BCR-ABL Transcript Level May Identify Patients at Risk of Progression in Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 7-9.	1.4	16
166	Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib. International Journal of Molecular Sciences, 2019, 20, 2226.	4.1	16
167	Rare gastrointestinal lymphomas: The endoscopic investigation. World Journal of Gastrointestinal Endoscopy, 2015, 7, 928.	1.2	16
168	Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319. British Journal of Haematology, 2001, 114, 230-232.	2.5	15
169	Increased phosphoâ€m‹scp›TOR‹/scp› expression in megakaryocytic cells derived from ‹scp›CD‹/scp›34+ progenitors of essential thrombocythaemia and myelofibrosis patients. British Journal of Haematology, 2012, 159, 237-240.	2.5	15
170	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. BMC Cancer, 2013, 13, 60.	2.6	15
171	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. Cancer, 2013, 119, 1177-1185.	4.1	15
172	Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. Frontiers in Pharmacology, 2015, 6, 226.	3.5	15
173	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. Haematologica, 2016, 101, e196-e199.	3.5	15
174	Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. Leukemia Research, 2017, 62, 77-83.	0.8	15
175	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. American Journal of Hematology, 2018, 93, E216-E219.	4.1	15
176	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica, 2020, 105, 1613-1620.	3.5	15
177	Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. PLoS ONE, 2015, 10, e0118801.	2.5	15
178	NF-Î²B localization in multiple myeloma plasma cells and mesenchymal cells. Leukemia Research, 2011, 35, 52-60.	0.8	14
179	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	17.0	14
180	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2014, 89, 743-750.	4.1	14

#	Article	IF	Citations
181	Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. Leukemia and Lymphoma, 2016, 57, 116-119.	1.3	14
182	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. Blood Advances, 2021, , .	5.2	14
183	Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. Leukemia Research, 2008, 32, 673-674.	0.8	13
184	Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. Leukemia, 2014, 28, 967-970.	7.2	13
185	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica, 2019, 104, 2241-2248.	3.5	13
186	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 53-54.	1.4	13
187	In vitro drugâ€induced cytotoxicity predicts clinical response to fludarabine in Bâ€cell chronic lymphocytic leukaemia. British Journal of Haematology, 1998, 102, 528-531.	2.5	12
188	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. European Journal of Haematology, 2014, 93, 207-213.	2.2	12
189	BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2019, 9, 764.	2.8	12
190	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
191	The multiâ€tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Realâ€world data. European Journal of Haematology, 2020, 105, 3-15.	2.2	12
192	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. Frontiers in Oncology, 2021, 11, 643490.	2.8	12
193	Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Frontiers in Oncology, 2021, 11, 684561.	2.8	12
194	Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in longâ€term followâ€up. Hematological Oncology, 2012, 30, 180-185.	1.7	11
195	Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	3.5	11
196	Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study. Haematologica, 2022, 107, 2661-2666.	3.5	11
197	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3â€year followâ€up. American Journal of Hematology, 2010, 85, 375-377.	4.1	10
198	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomideâ€“dexamethasone incorporated into double autologous transplantation. Annals of Hematology, 2013, 92, 1271-1280.	1.8	10

#	Article	IF	Citations
199	Standard therapies versus novel therapies in Hodgkin lymphoma. Immunology Letters, 2013, 155, 56-59.	2.5	10
200	Total body computed tomography scan in the initial workâ€up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€CLL1â€GISL study. American Journal of Hematology, 2013, 88, 539-544.	4.1	10
201	Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Annals of Oncology, 2013, 24, 1038-1044.	1.2	10
202	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplantation, 2014, 49, 485-491.	2.4	10
203	Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report. Anticancer Research, 2019, 39, 3949-3954.	1.1	10
204	Colony-Forming Cell Assay Detecting the Co-Expression of <i>JAK2</i>^{V617F} and <i>BCR-ABL1</i> in the Same Clone: A Case Report. Acta Haematologica, 2019, 141, 261-267.	1.4	10
205	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PETâ€2â€adapted HD0607 trial. Cancer Medicine, 2020, 9, 8735-8746.	2.8	10
206	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective realâ€world study. European Journal of Haematology, 2020, 104, 581-587.	2.2	10
207	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	4.1	10
208	Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts. Frontiers in Pharmacology, 2021, 12, 669469.	3.5	10
209	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. Blood, 2018, 132, 125-125.	1.4	10
210	Hypereosinophilia and subcutaneous heparin. Lancet, The, 1993, 342, 1371.	13.7	9
211	Evaluation of taxol cytotoxicity on B-CLL cells in vitro. Leukemia and Lymphoma, 1997, 26, 115-119.	1.3	9
212	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 10, 906-922.	2.1	9
213	Intrasomatic injection of corticosteroid followed by vertebroplasty increases early pain relief rather than vertebroplasty alone in vertebral bone neoplasms: preliminary experience. Skeletal Radiology, 2012, 41, 459-464.	2.0	9
214	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. Leukemia Research, 2013, 37, 943-947.	0.8	9
215	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. British Journal of Haematology, 2015, 168, 455-459.	2.5	9
216	The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. Journal of Hematology and Oncology, 2016, 9, 26.	17.0	9

#	Article	IF	Citations
217	TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment. Antioxidants, 2022, 11, 767.	5.1	9
218	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1357-1366.	2.5	8
219	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	7.2	8
220	Predictive value of the <scp>CLL</scp>â€<scp>IPI</scp> in <scp>CLL</scp> patients receiving chemoâ€immunotherapy as firstâ€line treatment. European Journal of Haematology, 2018, 101, 703-706.	2.2	8
221	Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib. In Vivo, 2019, 33, 1593-1598.	1.3	8
222	Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform. Anticancer Research, 2019, 39, 6965-6971.	1.1	8
223	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica, 2021, 106, 2345-2353.	3.5	8
224	Targeting BCL-2 as a Therapeutic Strategy for Primary ^{p210}BCR-ABL1-positive B-ALL Cells. In Vivo, 2020, 34, 511-516.	1.3	8
225	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	4.1	8
226	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. Blood, 2018, 132, 4511-4511.	1.4	8
227	In Vitro Sensitivity of B-CLL Cells to Fludarabine and Interferons. Leukemia and Lymphoma, 1995, 17, 449-453.	1.3	7
228	Analysis of the role of elution buffers on the separation capabilities of dielectrophoretic devices. Sensing and Bio-Sensing Research, 2016, 7, 162-167.	4.2	7
229	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€<scp>CLL</scp>1â€<scp>GISL</scp> study. European Journal of Haematology, 2016, 96, 36-45.	2.2	7
230	Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. Journal of Clinical Medicine, 2019, 8, 1695.	2.4	7
231	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
232	Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions. World Journal of Emergency Surgery, 2020, 15, 17.	5.0	7
233	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. Annals of Hematology, 2021, 100, 1743-1753.	1.8	7
234	Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Frontiers in Oncology, 2021, 11, 624405.	2.8	7

#	Article	IF	Citations
235	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 2021, 11, 73.	6.2	7
236	Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Hematological Oncology, 2022, 40, 1009-1019.	1.7	7
237	Alternation of Epirubicin and Mitoxantrone in CHOP-like Regimens Retains Efficacy and Reduces Overall Toxicity in Elderly Patients with High and Intermediate Grade Non-Hodgkin Lymphomas. Leukemia and Lymphoma, 2002, 43, 2319-2324.	1.3	6
238	Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: A clinical survey of 5 cases in Catania, Italy. Journal of Clinical Virology, 2011, 52, 284-287.	3.1	6
239	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. European Journal of Haematology, 2011, 86, 216-225.	2.2	6
240	Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need. Expert Review of Hematology, 2013, 6, 441-449.	2.2	6
241	Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. Future Oncology, 2017, 13, 3-6.	2.4	6
242	Rapid decline of Philadelphiaâ€'positive metaphases after nilotinib treatment in a cml patient expressing a rare e14a3 bcrâ€'abl1 fusion transcript: A case report. Oncology Letters, 2019, 18, 2648-2653.	1.8	6
243	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia, 2020, 34, 929-931.	7.2	6
244	A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. Journal of Clinical Medicine, 2020, 9, 2876.	2.4	6
245	Validation of the Alternative International Prognostic Scoreâ€Ł (AIPSâ€Ł): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the Oâ€ŁCLL1â€ŁGISL protocol. European Journal of Haematology, 2021, 106, 831-835.	2.2	6
246	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 684621.	2.8	6
247	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. Blood, 2011, 118, 294-294.	1.4	6
248	Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells. Journal of Clinical Medicine, 2021, 10, 5606.	2.4	6
249	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3â€yearfollowâ€up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Hematological Oncology, 2022, 40, 704-715.	1.7	6
250	Uncommon long-term survival in a patient with chronic myeloid leukemia. Acta OncolÃ³gica, 2009, 48, 1215-1216.	1.8	5
251	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11â€"12, 2013. Critical Reviews in Oncology/Hematology, 2014, 90, 181-189.	4.4	5
252	Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs. Leukemia and Lymphoma, 2015, 56, 1507-1509.	1.3	5

#	Article	IF	Citations
253	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	2.2	5
254	Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Medica, 2021, 63, 1-6.	0.8	5
255	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	1.4	5
256	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. European Journal of Haematology, 2022, 108, 178-189.	2.2	5
257	Immunological Subsets Characterization in Newly Diagnosed Relapsingâ€"Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 819136.	4.8	5
258	Network metaâ€analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. Hematological Oncology, 2022, 40, 987-998.	1.7	5
259	Role of thalidomide in previously untreated patients with multiple myeloma. Expert Review of Anticancer Therapy, 2008, 8, 1569-1580.	2.4	4
260	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene. American Journal of Hematology, 2011, 86, 993-997.	4.1	4
261	Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. Anticancer Research, 2020, 40, 5313-5317.	1.1	4
262	Serum free light chains and multiple myeloma: Is it time to extend their application?. Clinical Case Reports (discontinued), 2020, 8, 617-624.	0.5	4
263	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). The Hematology Journal, 2001, 2, 54-60.	1.4	4
264	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. Blood, 2012, 120, 2601-2601.	1.4	4
265	High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib. Blood, 2013, 122, 1495-1495.	1.4	4
266	Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques. PLoS ONE, 2015, 10, e0130360.	2.5	4
267	Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. Turkish Journal of Haematology, 2015, 32, 206-212.	0.5	4
268	Lymphoma of the cecum: a case report. International Surgery, 2002, 87, 12-4.	0.1	4
269	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. Cancers, 2022, 14, 1173.	3.7	4
270	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. Leukemia Research, 2010, 34, e217-e218.	0.8	3

#	Article	IF	Citations
271	Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?. Lancet Oncology, The, 2011, 12, 118.	10.7	3
272	Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment. Leukemia Research, 2012, 36, 1208-1209.	0.8	3
273	Towards a need to a â€œbiological Sokal riskâ€•in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia. Leukemia Research, 2012, 36, 803.	0.8	3
274	Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report. Journal of Medical Case Reports, 2016, 10, 315.	0.8	3
275	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. Leukemia, 2016, 30, 513-517.	7.2	3
276	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the) Tj ETQq0 0 1.0 rgBT /Overlock 10	1.8	3
277	Optimal Response in a Patient With CML Expressing BCRâ€“ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report. In Vivo, 2020, 34, 1481-1486.	1.3	3
278	Effectiveness of ibrutinib as firstâ€•line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€•bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	4.1	3
279	Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021042.	1.3	3
280	High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.. Blood, 2012, 120, 2790-2790.	1.4	3
281	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2015, 126, 4225-4225.	1.4	3
282	Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma. Current Medical Imaging, 2018, 14, 533-544.	0.8	3
283	Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma.. Blood, 2009, 114, 3662-3662.	1.4	3
284	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. Blood, 2018, 132, 4303-4303.	1.4	3
285	Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. Diagnostics, 2022, 12, 1051.	2.6	3
286	Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 554-557.	1.3	2
287	Double CEBPE-IGH rearrangement due to chromosome duplication and cryptic insertion in an adult with B-cell acute lymphoblastic leukemia. Cancer Genetics, 2011, 204, 563-568.	0.4	2
288	Infliximab therapy in hematologic malignancies: handle with care (Comment). Haematologica, 2012, 97, e26-e26.	3.5	2

#	Article	IF	Citations
289	A snapshot of asparaginaseâ€induced liver insufficiency. European Journal of Haematology, 2014, 92, 271-272.	2.2	2
290	A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?. Clinical Case Reports (discontinued), 2019, 7, 1629-1636.	0.5	2
291	How We Manage Smoldering Multiple Myeloma. Hematology Reports, 2020, 12, 8951.	0.8	2
292	The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large bâ€cell lymphoma. Clinical Case Reports (discontinued), 2021, 9, e03817.	0.5	2
293	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. Blood, 2013, 122, 770-770.	1.4	2
294	Lenalidomide and Pomalidomide Improve Function and Induce FcÎ³RI/CD64 in Multiple Myeloma Neutrophils. Biomedicines, 2021, 9, 1455.	3.2	2
295	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. Blood, 2013, 122, 3126-3126.	1.4	2
296	Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study. Cancers, 2021, 13, 6017.	3.7	2
297	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. Blood, 2020, 136, 54-55.	1.4	2
298	Pegylated Asparaginaseâ€Induced Liver Injury: A Caseâ€Based Review and Data From Pharmacovigilance. Journal of Clinical Pharmacology, 2022, 62, 1142-1150.	2.0	2
299	Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy. International Journal of Hematology, 2012, 96, 142-143.	1.6	1
300	Percutaneous transluminal angioplasty and stent implantation for aortic coarctation in haemophilia A patient with high-titre factor VIII inhibitors. Haemophilia, 2014, 20, e336-e338.	2.1	1
301	Elution time changes due to anomalous DEP effects in microchannels under uniform and non-uniform electric fields. Sensing and Bio-Sensing Research, 2016, 8, 59-64.	4.2	1
302	Unusual Karyotype in Acute Myelomonocitic Leukemia: A Case Report. Anticancer Research, 2019, 39, 4329-4332.	1.1	1
303	Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. Panminerva Medica, 2021, 63, 13-20.	0.8	1
304	A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic. Diagnostics, 2021, 11, 1502.	2.6	1
305	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2007, 110, 4672-4672.	1.4	1
306	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. Blood, 2013, 122, 4383-4383.	1.4	1

#	Article	IF	Citations
307	Management of Venous Thromboembolism (VTE) in Patients with Acute Leukemia: Results from a Multicenter Study. Blood, 2014, 124, 3688-3688.	1.4	1
308	Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry. Blood, 2015, 126, 2780-2780.	1.4	1
309	European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide. Blood, 2016, 128, 5680-5680.	1.4	1
310	Role of Imatinib Mesylate in Osteoblastogenesis.. Blood, 2007, 110, 1928-1928.	1.4	1
311	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 EuropeanLeukemia Net (ELN) Criteria.. Blood, 2009, 114, 3302-3302.	1.4	1
312	Stereotyped Subset #4 In Chronic Lymphocytic Leukemia Is Associated With Distinct Gene and Microrna Transcriptional Profile. Blood, 2013, 122, 1616-1616.	1.4	1
313	Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma. Blood, 2013, 122, 4238-4238.	1.4	1
314	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. Blood, 2016, 128, 4358-4358.	1.4	1
315	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	1.4	1
316	Low-Dose Cytarabine in Myelodysplastic Syndromes and Acute Leukemia. Acta Haematologica, 1986, 75, 125-126.	1.4	0
317	Treatment of newly diagnosed multiple myeloma. Current Hematologic Malignancy Reports, 2008, 3, 107-114.	2.3	0
318	Utility of Flow Cytometry as a Screening Tool for Transplant Donors for Chronic Lymphocytic Leukemia. Acta Haematologica, 2010, 123, 235-236.	1.4	0
319	Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia. Acta Haematologica, 2010, 124, 103-104.	1.4	0
320	Diagnosis of Blastic Phase of Chronic Myeloid Leukemia. Acta Haematologica, 2012, 127, 198-198.	1.4	0
321	Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients. Current Cancer Therapy Reviews, 2013, 9, 1-7.	0.3	0
322	Percutaneous transluminal aortic valve implantation for severe aortic valve stenosis in a patient with severe haemophilia A. Haemophilia, 2015, 21, e500-3.	2.1	0
323	Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome. Journal of Clinical Apheresis, 2016, 31, 443-447.	1.3	0
324	Pomalidomide: when expectations are understated. Future Oncology, 2017, 13, 1-2.	2.4	0

#	Article	IF	Citations
325	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. Blood, 2006, 108, 4981-4981.	1.4	0
326	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. Blood, 2006, 108, 4387-4387.	1.4	0
327	Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamathasone in Previously Treated Myeloma Patients.. Blood, 2007, 110, 2728-2728.	1.4	0
328	Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.. Blood, 2007, 110, 4307-4307.	1.4	0
329	Role of New Tyrosine Kinase Inhibitors in Osteoblastogenesis. Blood, 2008, 112, 4751-4751.	1.4	0
330	Variation of T-Reg and CD 200+ T- Lymphocytes After in Vitro Treatment with Active Drugs against CLL.. Blood, 2009, 114, 1239-1239.	1.4	0
331	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (â‰¥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	1.4	0
332	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. Blood, 2010, 116, 2273-2273.	1.4	0
333	Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY. Blood, 2011, 118, 2837-2837.	1.4	0
334	Histone Deacetylase Inhibitors Induce Cell Growth Inhibition and Apoptosis in NPM1-Mutated AML Cells: A Possible Role for Epigenetic Therapies in AML Carrying NPM1 Gene Mutations. Blood, 2011, 118, 2621-2621.	1.4	0
335	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. Blood, 2011, 118, 1682-1682.	1.4	0
336	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. Blood, 2012, 120, 930-930.	1.4	0
337	Incidence and Management Of Venous Thrombosis In Acute Leukemia: A Multicenter Study. Blood, 2013, 122, 3890-3890.	1.4	0
338	Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients. Blood, 2013, 122, 496-496.	1.4	0
339	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. Blood, 2013, 122, 2711-2711.	1.4	0
340	A Randomized Open-Label Study To Evaluate The Efficacy Of Azacitidine For Post-Remission Therapy Of Acute Myeloid Leukemia In Elderly Patients (QOLESS AZA-AMLE). Blood, 2013, 122, 3967-3967.	1.4	0
341	Role of Nuclear Heme Oxygenaseâ€1 in Bortezomib Induced Cell Death. FASEB Journal, 2015, 29, 897.2.	0.5	0
342	Contribution of High-Density Neutrophils to Multiple Myeloma Microenvironment Dysregulation. Blood, 2016, 128, 5643-5643.	1.4	0

#	Article	IF	Citations
343	Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Desamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network. Blood, 2018, 132, 5636-5636.	1.4	0
344	Role of TLR4 in the Activation of a Pro-Tumor Phenotype of Mesenchymal Stromal Cells in Mutiple Myeloma. Blood, 2018, 132, 1892-1892.	1.4	0
345	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. Blood, 2018, 132, 2023-2023.	1.4	0
346	Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study. Blood, 2018, 132, 3286-3286.	1.4	0
347	Long Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Real Life Experience. Blood, 2018, 132, 5669-5669.	1.4	0
348	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol. Blood, 2018, 132, 2934-2934.	1.4	0
349	VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience. Blood, 2019, 134, 4972-4972.	1.4	0
350	Inhibition of TLR4 Signaling Affects Mitochondrial Fitness Overcoming Bortezomib Resistance in Myeloma Plasma Cells. Blood, 2019, 134, 3073-3073.	1.4	0
351	Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. Blood, 2019, 134, 4868-4868.	1.4	0
352	Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways. Blood, 2019, 134, 4345-4345.	1.4	0
353	CXCL12/CXCR4 Axis Drives Mitochondrial Trafficking in Tumor Myeloma Microenvironment. Blood, 2021, 138, 2663-2663.	1.4	0
354	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	1.4	0
355	Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients. Blood, 2020, 136, 26-26.	1.4	0
356	An Integrative Unbiased Global Analysis of the Metabolic Adaptive Response to Tryptophan Deprivation in Classical Hodgkin Lymphoma. Blood, 2020, 136, 26-27.	1.4	0
357	The Heme Oxygenase-1/Carbon Monoxide Pathway Activates TLR4 Signaling Promoting Bortezomib Resistance in Multiple Myeloma Cells. Blood, 2020, 136, 13-14.	1.4	0